Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue

PartnershipPositive

AI Analysis

Summary

Merck and SciBrunch announced a collaboration to develop a preclinical KRAS-inhibiting molecular glue with potential payments up to $2.13 billion including $400 million upfront and milestone-based payments across multiple indications.

Importance:7/10

Sentiment:

0.70

KRAS inhibitormolecular gluepartnershippreclinicalmilestone payments

Related Companies

$MRK

Read the original article

Published by GEN - Genetic Engineering & Biotech News on September 29, 2026 10:01 PM

Read Original